AJ, S., H, X., S, G., I, N., P, R., D, H., & L, H. (2019). Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: Comparison between European and non-European population. Dove Medical Press.
Cita Chicago Style (17a ed.)AJ, Savitz, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, y Hargarter L. Efficacy and Safety of Paliperidone Palmitate 3-month Versus 1-month Formulation in Patients with Schizophrenia: Comparison Between European and Non-European Population. Dove Medical Press, 2019.
Cita MLA (8a ed.)AJ, Savitz, et al. Efficacy and Safety of Paliperidone Palmitate 3-month Versus 1-month Formulation in Patients with Schizophrenia: Comparison Between European and Non-European Population. Dove Medical Press, 2019.